Plasma miRNA-based signatures in CRC screening programs.

Clicks: 194
ID: 38397
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #24 of 32 articles by views in International journal of cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607-0.682), 0.670 (0.626-0.714) and 0.682 (0.580-0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most.
Reference Key
zanutto2019plasmainternational Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zanutto, Susanna;Ciniselli, Chiara Maura;Belfiore, Antonino;Lecchi, Mara;Masci, Enzo;Delconte, Gabriele;Primignani, Massimo;Tosetti, Giulia;Dal Fante, Marco;Fazzini, Linda;Airoldi, Aldo;Vangeli, Marcello;Turpini, Francesca;Rubis Passoni, Giovanni Giuseppe;Viaggi, Paolo;Arena, Monica;Motta, Roberta Ilaria Olimpia;Cantù, Anna Maria;Crosta, Cristiano;De Roberto, Giuseppe;Iannuzzi, Francesca;Cassinotti, Andrea;Dall'Olio, Valentina;Tizzoni, Laura;Sozzi, Gabriella;Meroni, Emanuele;Bisanti, Luigi;Pierotti, Marco Alessandro;Verderio, Paolo;Gariboldi, Manuela;
Journal International journal of cancer
Year 2019
DOI
10.1002/ijc.32573
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.